New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

Top 5 Healthcare Headlines for April 28-May 4, 2025:

Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials

Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025.

MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial

MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy.

Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial

Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option.

UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks

UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study.

Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients

Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.

Articles

The recent healthcare updates highlight significant advancements in various therapeutic areas. Obicetrapib has shown substantial LDL-C reduction in ASCVD patients, both as monotherapy and combined with ezetimibe. MAR001, targeting ANGPTL4, has effectively reduced remnant cholesterol and triglycerides in high-risk patients. Zervimesine has demonstrated potential in slowing geographic atrophy lesion growth in AMD. UBX1325 has matched aflibercept in improving visual acuity for diabetic macular edema. Roflumilast foam 0.3% has proven effective and safe for treating scalp and body psoriasis, with an FDA decision anticipated soon.

An audio recap of the top 5 stories in healthcare news from the week of 04/28-05/04.



News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatology

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

HCPLive 5 Stories in Under 5: Week of 05/04

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Although long-term use of omalizumab for patients with 

 is known to be safe and well-tolerated, new findings suggest that the most common side effects seen among 32.9% of those treated with omalizumab include headaches, fatigue, and flu-like symptoms.

These findings were the result of an analysis looking at omalizumab’s side effects in real-world settings. This study on patients with chronic urticaria was authored by Reineke Soegiharto, from the Department of Dermatology/Allergology at the University Medical Centre Utrecht in the Netherlands.

Soegiharto and coauthors highlighted that real-world studies are necessary to elucidate omalizumab’s long-term safety profile and, thereby, to improve personalized medicine in an era where newer therapies for chronic urticaria have begun to emerge.

“To this end, we investigated the spectrum of side effects of omalizumab in [chronic urticaria] patients by assessing the prevalence of reported side effects and identifying determinants for the reporting of side effects in a large, long-term real-world cohort study,” Soegiharto and colleagues wrote.

In 14 specialized care centers for patients with urticaria, the investigative team conducted their research using a retrospective, international, multicentre cohort analysis design. These had been designated as Urticaria Centres of Reference and Excellence (UCAREs) and were located in 10 countries.

The teams' aim in their analysis was to assess the drug survival and tolerability of omalizumab among those with chronic urticaria. Clinicians would, at each study site, record whether participants experienced any side effects during omalizumab therapy that were considered related to the drug by the treating physician. These effects were documented by the investigators as "yes," "no," or "unknown" in the medical records.

Side effects reported by the clinicians which are deemed to be omalizumab-associated were extracted from medical records, based on descriptions from either physicians or patients themselves. Such adverse events were classified by Soegiharto and colleagues using system organ classes as defined by the Medical Dictionary for Regulatory Activities (MedDRA).

Additional collected data included baseline patient demographic information, disease control/activity scores at both the point of initiation and completion of omalizumab use, and details about the treatment. Disease control was assessed by the investigators utilizing the Urticaria Control Test (UCT), whereas they determined disease activity through the use of the Weekly Urticaria Activity Score (UAS7).

When disease activity scores were missing, the investigative team inferred treatment responses and timing of onset using clinicians’ notes. All centers taking part in the study would, to improve understand the context and practices that might impact side effect reporting, fill out a questionnaire regarding their consultation approaches.

The study ended up with 1859 individuals included as subjects, with 32.9% having reported experiencing side effects while using omalizumab treatment. However, those reporting rates varied considerably across the centers that were evaluated, ranging from 0% - 75.5%. The most commonly reported adverse events were shown to be fatigue among 15.8%, headaches in 11.6%, and flu-like symptoms in 9.3%.

Notably, Soegiharto et al did not observe cases indicative of anaphylaxis. Additionally, they did not find any new and frequently occurring side effects. Hair loss was reported by 2.9% of the study's subjects, and among those with sufficient data, it was noted that 21.1% had their treatment modified as a result of this issue. 

The investigative team, in assessing factors linked to side effect experiences, found that those in this group were more likely to be female (78.3% versus 68.6%, 

 < .001). They also were more likely to have poorer disease control at the point of baseline (mean UCT score: 4.0 versus 6.0, 

 < .001). The team further highlighted that slower onset of clinical response—defined as UAS7 < 7 or UCT > 11 within 4 weeks—was observed compared to subjects without side effects (42.6% versus 59.5%, 

The proportion of participants attaining a complete or good response by conclusion of their course of treatment (UAS7 < 7 or UCT > 11) was found by the team to be lower among subjects showing side effects (72.3% versus 84.4%, 

Despite such conclusions, the investigators reported that only 2.4% of subjects discontinued their medication due to side effects. Among individuals reporting side effects, 5.5% who had not reached sufficient disease control (UAS7 ≥ 7 or UCT 3–11) and 12.8% who attained good or complete response continued their course of omalizumab treatment.

“The reporting of side effects was associated with insufficient omalizumab response, suggesting the increased burden in CU patients and highlighting the importance of achieving complete disease control in CU patients,” they concluded.

 “Although side effects are currently rarely a reason for treatment discontinuation, the availability of new alternative therapies will increase the impact of side effects on treatment decisions.”

Soegiharto R, Van der Wind E, Alizadeh Aghdam M, et al (2025). Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World Study. Clin Exp Allergy. 

M Maurer, TB Casale, SS Saini, et al., “Dupilumab in Patients With Chronic Spontaneous Urticaria (LIBERTY-CSU CUPID): Two Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials,” Journal of Allergy and Clinical Immunology 154, no. 1 (2024): 184–194.

Omalizumab is generally safe for chronic urticaria, but 32.9% of patients report side effects like headaches, fatigue, and flu-like symptoms. A multicenter study across 14 specialized centers assessed omalizumab's long-term safety, revealing that side effects were more common in females and those with poorer disease control. Despite side effects, only 2.4% discontinued treatment. The study emphasizes the importance of achieving complete disease control, as side effects correlate with insufficient response. Emerging therapies may influence treatment decisions due to side effect considerations.

This multinational, retrospective study highlights the effect of omalizumab on chronic urticaria among patients at multiple urticaria care centers.

Omalizumab Side Effects in Patients With Chronic Urticaria Highlighted

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 could be a potential risk factor for incident dementia, mediated through the reduction of brain structures.

“With the rising impact of dementia around the world, identifying risk factors and implementing preventive measures is essential,” said lead investigator Yacong Bo, PhD, of Zhengzhou University in China, in a statement. 

“While none of us can change our chronological age, we can influence our biological age through lifestyle factors such as diet and exercise.”

Research has suggested that biological age, determined by factors such as lung function, blood pressure, and cholesterol, is linked to dementia. A study published this year reported that shorter protective caps on chromosomes called telomeres, a proposed marker of accelerated biological aging, may be linked to an increased risk of dementia.

 The study had shown that compared with people with longer leukocyte telomeres, people with shorter ones had a 19% greater risk of dementia.

Another study also showed that individuals in the highest quartile of phenotypic age acceleration, an indicator for accelerated biological aging calculated by 9 clinical blood biomarkers and chronological age, had the greatest dementia risk.

Although research has suggested a link between biological aging and dementia, limited data exist on this association. Investigators aimed to investigate the relationship between biological age and incident dementia, along with examining the underlying neurobiological mechanisms.

Leveraging data from the UK Biobank, the study included 280,918 participants (mean chronological age: 56.80 years; 54.59%) who did not have diagnosed dementia at baseline. Biological age was assessed from clinical traits using the Klemera-Doubal method biological age (KDM-BA) and PhenoAge algorithms. Biomarkers examined for biological age included lung function, blood pressure, cholesterol, average cell volume, ad white blood cell count. The team evaluated the genetic risk of dementia using the apolipoprotein E (APOE) ε4 genotype and polygenic risk scores (PRSs).

Investigators evaluated the associations of biological age and the combined effect of genetic risk and biological age with dementia using Cox proportional hazard regression models. They conducted a mediation analysis to assess the potential roles of brain structures, such as gray matter volume, cortical mean thickness, and cortical surface area, in the link between biological age and dementia.

Over a median follow-up of 13.58 years, 4770 participants developed dementia. The analysis showed every increase in KDM-BA accelerations and PhenoAge accelerations were linked to a 14% (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.10 – 1.18) and 15% (HR, 1.15; 95% CI, 1.12 – 1.19) greater incidence of dementia, respectively.

Participants who later developed dementia had an average chronological age of 65 years at baseline, compared to an average age of 57 years among those who did not develop dementia. Those who developed dementia had a mean biological age of 55 years, compared with individuals with no dementia who had a mean age of 45 years.

Participants with APOE ε4 and the highest PhenoAge accelerations had the greatest risk of dementia (HR, 4.20; 95% CI, 3.69 – 4.78) compared with those with non-APOE ε4 and the lowest PhenoAge accelerations (

 < .001). Participants with the most advanced biological age were about 30% more likely to develop dementia than those without.

The study did not find any significant medication effects of polygenic risk scores on the association between biological age accelerations and dementia when examining the KDM-BA acceleration (

 = .279). They also did not find a significant effect of APOE ε4 on the association between KDM-BA accelerations and dementia (

Furthermore, the mediation analysis demonstrated that the identified gray matter volume, cortical mean thickness, and cortical surface area slightly mediated the association between biological age accelerations and incident dementia, ranging from 6.64% to 17.98% of participants.

Although this study does not prove that advanced biological age causes dementia, the research shows an association.

“These brain structure changes explain some, but not all, of the association between advanced biological age and dementia,” Bo said. “These results support the hypothesis that advanced biological age may contribute to the development of dementia by causing a widespread change in brain structures.

Bo Y, Sun L, Hou S, Zhang F, Zhang H, Feng X, Zhuo S, Feng S, Chang H, Zhang X, Wang Z, Yu Z, Zhao X. Associations of Accelerated Biological Aging With Dementia and the Mediation Role of Brain Structure: Findings From a Longitudinal Study. Neurology. 2025 May 27;104(10):e213616. doi: 10.1212/WNL.0000000000213616. Epub 2025 Apr 30. PMID: 40305743.

Derman, C. Shorter Telomere Length Linked to Increased Risk of Stroke, Dementia, Depression. HCPLive. February 3, 2025. 

https://www.hcplive.com/view/shorter-telomere-length-linked-increased-risk-stroke-dementia-depression

Does Your Biological Age Affect Your Risk of Dementia? News Wise. April 24, 2025. 

https://www.newswise.com/articles/does-your-biological-age-affect-your-risk-of-dementia

 Associations of combined accelerated biological aging and genetic susceptibility with incident dementia: a prospective study in the UK Biobank. 

, 425 (2024). https://doi.org/10.1186/s12916-024-03640-4

Advanced biological aging is linked to an increased risk of dementia, potentially mediated by changes in brain structures. Biological age, influenced by factors like lung function and cholesterol, can be modified through lifestyle choices. The study used data from the UK Biobank, assessing biological age with KDM-BA and PhenoAge algorithms. Results showed that higher biological age accelerations were associated with a greater incidence of dementia. Genetic factors like APOE ε4 also contributed to risk. Brain structure changes partially mediated the relationship between biological age and dementia, supporting the hypothesis of biological age's role in dementia development.

Advanced biological aging significantly associated with the dementia risk, a new study found.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

 Biological Aging May Be a Risk Factor for Incident Dementia

Jeemin Kwon, MD, is an internal medicine resident at the University of California Los Angeles David Geffen School of Medicine.

GI Symptom Related-Anxiety Drives Restrictive Eating in IBS

New research presented at Digestive Disease Week (DDW) 2025 offers novel insight into the complex relationship between diet, anxiety, and the gut microbiome in patients with 

Study findings were presented by Jeemin Kwon, MD, an internal medicine resident at the University of California Los Angeles David Geffen School of Medicine, and shed light on the critical role that gastrointestinal (GI) symptom–related anxiety plays in shaping dietary patterns and altering gut microbiome composition among patients with IBS.

“We are beginning to realize, even besides general anxiety disorder or depression, which definitely run comorbid with IBS and other disorders of gut brain interaction, it's really the anxiety even of having GI symptoms that plays a key role in terms of the behaviors that we see people doing to control their GI symptoms,” Kwon explained to 

While it’s long been known that meal-related symptoms are common in IBS—affecting more than 80% of patients— Kwon says the field is now gaining clarity on what drives food avoidance behaviors. Foods high in FODMAPs, along with gluten and dairy, are widely recognized triggers, but many patients restrict their diets beyond what guidelines recommend, often without systematic reintroduction, which may negatively affect nutritional diversity and long-term gut health.

According to Kwon’s research, the key driver behind this restriction may not be symptoms themselves, but rather the 

“We were really surprised to see that it was actually the GI symptom-related anxiety, rather than the actual symptoms themselves, that drove most of that relationship between having IBS and following a restrictive diet,” she said.

The study also leveraged shotgun metagenomic sequencing to explore downstream effects on the microbiome and found notable differences in certain species abundances related to fermentation pathways as well as related reductions in pathways such as pyruvate fermentation to butanoate implying less short chain fatty acid production.

“If you think about it, it makes a lot of sense that reducing lactose and FODMAPS is going to lead to less fermentation, and that's probably why a lot of these folks have that symptom relief in terms of bloating and abdominal pain,” Kown said. “But now we're kind of raising the question, do we need to be concerned? Are there more long term negative effects in terms of what these restrictive diets are doing to our microbiome?”

Looking ahead, Kwon says future research needs to explore the hypothesis that targeting GI symptom-related anxiety in the clinical setting could be helpful for patients with IBS. She also points to the need for longitudinal data to explore the long-term effects of reductions in fermentation on gut health and a more comprehensive understanding of the gene pathways being upregulated or downregulated and how they play into the gut-brain axis for IBS.

Editors’ note: Kwon has no relevant disclosures.

Kwon J, Mahurkar-Joshi S, Fasulo C, et al. GI SYMPTOM-RELATED ANXIETY DRIVES RESTRICTIVE EATING IN IBS, LEADING TO GUT MICROBIOME ALTERATIONS AND POTENTIAL NEGATIVE EFFECTS ON GUT HEALTH. Abstract presented at Digestive Disease Week 2025 in San Diego, CA, from May 3 - May 6, 2025.

Videos

Jeemin Kwon, MD, describes the role GI symptom-related anxiety plays in shaping dietary patterns and altering the gut microbiome in patients with IBS.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include major cholesterol-lowering breakthroughs with obicetrapib and MAR001, promising age-related macular degeneration (AMD) and diabetic macular edema (DME) trial results for zervimesine and UBX1325, and new efficacy data for roflumilast foam in treating scalp and body psoriasis.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of May 04, 2025—let’s jump in!

Once-daily oral obicetrapib, as an adjunct to statins, significantly reduced LDL-C in patients with ASCVD who do not respond sufficiently to standard therapy in two Phase 3 trials. Announced by NewAmsterdam Pharma, and presented as late-breaking research at the European Atherosclerosis Society (EAS) Congress 2025, obicetrapib cut LDL-C by more than 30% as monotherapy and nearly 50% when combined with ezetimibe.

A novel cholesterol-lowering drug may offer a new approach to reducing cardiovascular risk in patients with elevated triglycerides and remnant cholesterol, beyond the reach of traditional therapies. Announced by Marea Therapeutics on May 7, 2025, and presented at the 93rd EAS Congress, MAR001, a first-in-class monoclonal antibody targeting ANGPTL4, reduced remnant cholesterol and triglycerides by more than 50% compared with placebo at 12 weeks.

Oral zervimesine (CT1812) successfully lowered lesion growth in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in topline results from the Phase 2 MAGNIFY trial. Zervimesine slowed the trajectory of GA by approximately 28.6%, and GA lesion growth by 28.2% at 18 months, compared with placebo.

UBX1325 (foselutoclax) demonstrated noninferior vision gains compared with aflibercept for diabetic macular edema (DME) across 36 weeks in the Phase 2b ASPIRE study. UBX1325 treatment led to vision gains of >5 letters from baseline, indicating non-inferiority to aflibercept at 9 of 10 points through the study period.

Roflumilast foam 0.3% (Zoryve) showed significant efficacy in treating scalp and body psoriasis, achieving rapid symptom relief and high success rates in clinical assessments in the Phase 3 ARRECTOR study. A regulatory decision from the US Food and Drug Administration (FDA) for roflumilast foam 0.3% for scalp and body plaque psoriasis is expected by the end of May 2025.

Recent advancements in healthcare include significant cholesterol-lowering results from obicetrapib and MAR001, promising outcomes for age-related macular degeneration and diabetic macular edema treatments, and new efficacy data for roflumilast foam in psoriasis management. Obicetrapib, in Phase 3 trials, showed substantial LDL-C reduction, while MAR001, a monoclonal antibody, cut remnant cholesterol and triglycerides by over 50%. Zervimesine and UBX1325 demonstrated efficacy in reducing lesion growth and improving vision, respectively. Roflumilast foam proved effective for psoriasis, with an FDA decision anticipated soon.

Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.

Atherosclerotic Cardiovascular Disease

Geographic Atrophy

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

The HCPFive: Top News for Healthcare Providers from the Week of 05/04

An analysis of several datasets cataloguing the switch revealed that dosing can be extended up to 2 weeks for patients with nAMD who received prior anti-VEGF therapy.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Switching to Aflibercept 8 mg in Treatment-Experienced Patients with Ted Leng, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

COVID-19 vaccination had a particularly protective effect in males and those with anxiety or depression.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

COVID-19 Vaccination Protects Against New-Onset, Post-Infection Fibromyalgia 

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

New Phase 3 Data on Icotrokinra Suggest Efficacy for Genital, Scalp Psoriasis

A study reveals key risk factors for anaphylaxis from non-severe drug hypersensitivity, emphasizing the need for caution in drug administration.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

NSAIDs, H2 Blockers, and Penicillin Linked to Greater Anaphylaxis Risk from Mild Drug Reactions

Adolescent gout rates are rising globally, highlighting the need for early intervention and lifestyle changes to mitigate health risks.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Global Rates of Gout Rising in Young Adults 

The recent trial indicates that the oral treatment gildeuretinol reduces GA lesion growth rates, as well as achieving better BCVA scores.

SAGA Trial Results for Gildeuretinol Treating Geographic Atrophy with David Boyer, MD

Elizabeth Spencer, MD, MS, is an assistant professor of pediatrics in the division of pediatric Gastroenterology at the Icahn School of Medicine at Mount Sinai and at the Mount Sinai Kravis Children’s Hospital.

A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and efficacy in this patient population.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

New Research Supports GLP-1 RA Use in IBD for Weight Loss, Disease Control

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Use of efruxifermin did not result in a significant reduction in fibrosis without worsening of MASH at week 36 compared with placebo in the phase 2b SYMMETRY trial.

Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH Cirrhosis Trial

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

Study Supports Adalimumab Biosimilar Interchangeability for Patients with Psoriasis

An expert discusses how chronic hand eczema (CHE) diagnosis relies on clinical features such as erythema, scaling, vesicles, hyperkeratosis, fissures, and erosions, which must be distinguished from atopic dermatitis through a comprehensive patient history and full-body examination.

Video Series

Insights

 Insights page is a resource for professional video interviews with leading clinical experts and investigators across all specialties of medicine.

Latest News

HCPLive 5 Stories in Under 5: Week of 05/04

Omalizumab Side Effects in Patients With Chronic Urticaria Highlighted

Biological Aging May Be a Risk Factor for Incident Dementia

GI Symptom Related-Anxiety Drives Restrictive Eating in IBS

The HCPFive: Top News for Healthcare Providers from the Week of 05/04